FDA Proposes Restricting 510(k) Use of Predicate Devices Over 10 Years Old
FDA proposes limiting 510(k) submissions to predicate devices cleared within the last 10 years.
Why it matters: Legal and compliance teams at medical device companies must adjust 510(k) submission strategies to comply with the new predicate device age limit, impacting clearance pathways, reimbursement timing, and market entry risks.
- FDA proposes a 10-year limit on predicate devices used in 510(k) submissions, narrowing clearance options.
- The proposal was detailed alongside an October 2026 update to the National Law Review’s medical device regulatory guide.
- FDA’s Payor Communication Task Force aims to coordinate earlier insurance coverage decisions with FDA marketing authorizations.
- The Total Product Life Cycle Advisory Program (TAP) Pilot encourages cross-stakeholder collaboration early in product development to align regulatory and reimbursement strategies.
The FDA has proposed updating its 510(k) clearance pathway by restricting manufacturers to use predicate devices cleared within the past 10 years. This restriction narrows which existing devices can be cited to demonstrate substantial equivalence, a key component in obtaining 510(k) authorization. Traditionally, predicate devices could be older than this, easing clearance for new products.
The National Law Review’s updated medical device launch guide, released in October 2026, highlights these FDA changes, emphasizing the need for updated patent and regulatory strategies.
Understanding 510(k): This FDA pathway requires showing a new device is as safe and effective as a legally marketed predicate device. The proposed 10-year predicate limit means companies may need to pivot to newer devices or other FDA pathways, potentially affecting time to market.
The FDA also operates a Payor Communication Task Force designed to speed insurance coverage decisions after regulatory clearance. This task force facilitates better alignment between manufacturers and insurance payors to address coverage delays that can follow FDA authorization.
Similarly, the Total Product Life Cycle Advisory Program (TAP) Pilot promotes early, coordinated dialogue among sponsors, FDA regulators, payors, and patient groups. This collaboration seeks to identify reimbursement and regulatory challenges earlier in development.
These initiatives affect legal, compliance, and commercial functions. Medical device clearances now require integrated planning to address patent timing, FDA requirements, and payer coverage. Compliance teams should anticipate that FDA clearance under the updated 510(k) rule will not guarantee reimbursement, which remains a separate and critical hurdle.
For example, Medicines360’s $82 million investment over six years to develop and launch the Liletta hormonal IUD illustrates the complex interplay of regulatory, reimbursement, and legal factors in bringing affordable devices to market.
By the numbers:
- 10 years — Proposed maximum age for predicate devices under new FDA 510(k) rule
- October 2026 — Date of National Law Review’s updated medical device launch guide
- $82 million — Investment by Medicines360 to develop Liletta hormonal IUD
Yes, but: The FDA's proposal has not yet been finalized; manufacturers can provide feedback before the rule takes effect, expected by late 2026.
What's next: The FDA is expected to issue a final rule on the 510(k) predicate device limit in late 2026. Industry stakeholders should monitor public comment periods and adjust development plans accordingly.